local
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
Summary by Denton News Editorial Desk · Byline on the source page: By AbbVie , as published by Denton Record-Chronicle
· June 26, 2026
· 1 min read
Photo: Denton Record-Chronicle · view original
Story provenance No corrections
Summary created by Denton News Editorial Desk — automated, rule-governed Byline on source page By AbbVie, as published by Denton Record-Chronicle Original story Read at the source Source published Jun 26, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key takeaway A medication has been approved for use in children as young as six with specific skin and joint diseases.
In Denton , patients with certain conditions now have a new treatment option. A medication has been approved for use in children as young as six with specific skin and joint diseases. This approval is for moderate to severe cases.
The treatment comes in different forms to accommodate various patient needs. Further information about this development can be found through the Denton Record-Chronicle, including details on administration and specific patient requirements.
Why this matters
Local news anchors readers in their community — the people, places, and decisions that shape day-to-day life. Denton News covers these stories because national outlets often won't.
About this story
As published by Denton Record-Chronicle . Denton News surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Denton Record-Chronicle . Have a tip or correction? Contact our newsroom .
Category: local ·
Published: June 26, 2026 ·
Source: Denton Record-Chronicle ·
Reading time: 1 min
Frequently asked about this story
What is this story about? In Denton, patients with certain conditions now have a new treatment option. A medication has been approved for use in children as young as six with specific skin and joint diseases. This approval is…
When was this published? This article was first published on June 26, 2026 by Denton Record-Chronicle and curated for Denton News readers.
Who reported this story? This story was reported by By AbbVie at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from Denton News, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter